Summary
Research indicates that raising levels of the Klotho protein could potentially delay aging and enhance health across various systems. In experiments, mice that produced more of the secreted Klotho (s-KL) showed improvements in muscle strength, bone density, cognitive abilities, and they lived 15–20% longer.
This treatment encouraged neuron growth, decreased muscle fibrosis, and offered bone protection, especially in female mice, hinting at broad health benefits. Although applications for humans are still being explored, these results present s-KL as a promising candidate for therapies aimed at fostering healthy aging.
Key Facts
- Longer Lifespan: Mice that produced increased amounts of Klotho lived 15–20% longer.
- Stronger Body: Those treated exhibited improved muscle, bone, and cognitive health.
- Therapy Potential: Scientists are working on Klotho-based treatments targeting aging.
As we age, losing muscle and bone mass becomes common, leading to increased frailty and a higher risk of falls and injuries. Additionally, cognitive decline often occurs due to neuronal degeneration, while conditions like Alzheimer’s and Parkinson’s become more prevalent. In an aging society, addressing these challenges is a primary focus of ongoing research.
In a recent article published in Molecular Therapy, a team of researchers led by Professor Miguel Chillón from ICREA at INc-UAB demonstrated that enhancing levels of the secreted Klotho protein (s-KL) can improve the aging process in mice.
The study involved treating younger mice with gene therapy that prompted their cells to secrete more s-KL. At 24 months of age, which roughly correlates to 70 years for humans, improvements were seen in their muscle, bone, and cognitive health.
“Our team has been investigating the Klotho protein for its therapeutic potential against neurodegenerative diseases. This study aimed to assess whether s-KL might also support healthy aging by evaluating various factors,” says Miguel Chillón.
The treated mice experienced a longer life with better physical performance, larger muscle fibers, and reduced fibrosis, indicating healthier muscles. Additionally, notable advancements in bone health were detected, especially in females, preserving critical bone structure and suggesting protective effects against osteoporosis.
Furthermore, the study found that treatment with s-KL stimulated the formation of new neurons and boosted immune response in the hippocampus, potentially leading to cognitive enhancements.
The method used involved viral vectors that introduced the genetic code for s-KL into the animals’ cells, promoting self-production of the protein. These vectors were administered both intravenously and directly into the brain, ensuring brain cells also generated s-KL.
“Now we have viral vectors that can effectively reach the brain through IV administration, which could simplify translating this therapy to humans,” notes Joan Roig-Soriano, a researcher at INc-UAB and the article’s lead author.
While administering the protein directly as a drug remains an option, the team is still searching for efficient delivery methods that ensure it reaches target organs. The research group has already patented methods for using Klotho in treating cognitive deficits, leading to three additional patents for addressing muscle and bone issues, as well as developing therapies aimed at increasing longevity.
“If we can finalize a reliable delivery method, s-KL could play a significant role in enhancing quality of life and promoting a healthier society,” the researchers conclude.
